skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Very Long-Term Outcomes of the Carpentier-Edwards Perimount Valve in Aortic Position

The Annals of thoracic surgery, 2015-03, Vol.99 (3), p.831-837 [Peer Reviewed Journal]

The Society of Thoracic Surgeons ;2015 The Society of Thoracic Surgeons ;Copyright © 2015 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved. ;ISSN: 0003-4975 ;EISSN: 1552-6259 ;DOI: 10.1016/j.athoracsur.2014.09.030 ;PMID: 25583467

Full text available

Citations Cited by
  • Title:
    Very Long-Term Outcomes of the Carpentier-Edwards Perimount Valve in Aortic Position
  • Author: Bourguignon, Thierry, MD ; Bouquiaux-Stablo, Anne-Lorraine, MD ; Candolfi, Pascal, PhD ; Mirza, Alain, MD ; Loardi, Claudia, MD ; May, Marc-Antoine, MD ; El-Khoury, Rym, MD ; Marchand, Michel, MD ; Aupart, Michel, MD
  • Subjects: Adolescent ; Adult ; Aged ; Aged, 80 and over ; Aortic Valve - surgery ; Bioprosthesis ; Cardiothoracic Surgery ; Female ; Heart Valve Prosthesis ; Humans ; Male ; Middle Aged ; Prosthesis Design ; Prosthesis Failure ; Reoperation - statistics & numerical data ; Retrospective Studies ; Surgery ; Time Factors ; Treatment Outcome ; Young Adult
  • Is Part Of: The Annals of thoracic surgery, 2015-03, Vol.99 (3), p.831-837
  • Description: Background The Carpentier-Edwards Perimount pericardial bioprosthesis (Edwards Lifesciences, Irvine, CA) has demonstrated good long-term outcomes, but its durability remains unclear depending on age at implantation. We report our 20-year experience with the Perimount valve implanted in the aortic position, with particular attention to the probability and time to reoperation required due to bioprosthesis deterioration. Methods From 1984 to 2008 at our center, 2,659 patients (mean age, 70.7 ± 10.4 years) underwent aortic valve replacement using the Perimount pericardial bioprostheses. Patients were prospectively followed on an annual basis (mean 6.7 ± 4.8 years, range 0 to 24.6 years) with an echocardiogram at the time of follow-up. Cumulative follow-up was 18,404 valve-years. Bioprosthesis structural valve deterioration was determined by strict echocardiographic assessment. Results Overall operative mortality was 2.8%. Actuarial survival rates including early deaths averaged 52.4% ± 1.2%, 31.1% ± 1.4%, and 14.4% ± 1.7% after 10, 15, and 20 years of follow-up, respectively. Age-stratified freedom from reoperation due to structural valve deterioration at 15 and 20 years was 70.8% ± 4.1% and 38.1% ± 5.6%, respectively, for the group aged 60 years or less, 82.7% ± 2.9% and 59.6% ± 7.6% for those 60 to 70 years, and 98.1% ± 0.8% at 15 years and above for the oldest group. Expected valve durability is 19.7 years for the entire cohort. Conclusions With a low rate of valve-related events at 20 years, and particularly a low rate of structural valve deterioration, the Carpentier-Edwards Perimount pericardial bioprosthesis remains a reliable choice for a tissue valve in the aortic position, especially in patients over 60 years of age.
  • Publisher: Netherlands: Elsevier Inc
  • Language: English
  • Identifier: ISSN: 0003-4975
    EISSN: 1552-6259
    DOI: 10.1016/j.athoracsur.2014.09.030
    PMID: 25583467
  • Source: GFMER Free Medical Journals
    MEDLINE
    Alma/SFX Local Collection
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait